Susanne Meza-Keuthen
Research Subjects
Research Interests
Susanne Meza-Keuthen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- John P. Jones Iii
WPLab, USA
3 shared publications - William Parker
Surgery Durham NC 27710 Duke University Medical Center
3 shared publications - Zacharoula Konsoula
WPLab, USA
3 shared publications - Lauren Williamson
Northern Kentucky University, USA
2 shared publications - Emily Talmage
WPLab, USA
1 shared publication - Matthew Harker
WPLab, USA
1 shared publication
Latest Publications
- Open Access
- 7 September 2026
- Published by MDPI AG in Preprints.org
Considering the Acetaminophen/Autism Connection in the Light of New Evidence
Numerous lines of evidence have previously allowed us to conclude that exposure of susceptible individuals to acetaminophen triggers many if not most cases of autism spectrum disorders (ASD), which have steadily increased in the US since 1980. Reasons for increasing acetaminophen exposure early in life include the switch from aspirin to acetaminophen in the early 1980s, dramatically increased marketing of acetaminophen in the 1990s, the development of acetaminophen use for opioid sparing protocols in response to the opioid crisis of the 2010s, and continued use of acetaminophen for vaccination as the vaccine schedule increased between 1980 and the present time. More recently, two sets of data from the US, one from the California Public School system and another from the NIH-sponsored ECHO study, indicate that the prevalence of autism spectrum disorders (ASD) is increasing dramatically in a manner dependent on low socioeconomic status. Some evidence suggests that a potential adverse drug-drug interaction between acetaminophen and cannabis use disorder may underlie this trend, with an increase in cannabis use disorder resulting from the legalization of recreational cannabis use. Although increasing use of acetaminophen and potentially changing environmental factors that enhance acetaminophen toxicity can explain the sustained rise in ASD, data consistent with the acetaminophen/autism model continue to be misinterpreted by those considered experts in the field, hampering progress. Most errors involve over-correction for mediating factors in large sibling-controlled studies, although more recent data involving socioeconomic-dependent disparities in ASD prevalence have also been misinterpreted.
- 7 September 2026
- Published by MDPI AG in Preprints.org
Open AccessConsidering the Acetaminophen/Autism Connection in the Light of New Evidence
Numerous lines of evidence have previously allowed us to conclude that exposure of susceptible individuals to acetaminophen triggers many if not most cases of autism spectrum disorders (ASD), which have steadily increased in the US since 1980. Reasons for increasing acetaminophen exposure early in life include the switch from aspirin to acetaminophen in the early 1980s, dramatically increased marketing of acetaminophen in the 1990s, the development of acetaminophen use for opioid sparing protocols in response to the opioid crisis of the 2010s, and continued use of acetaminophen for vaccination as the vaccine schedule increased between 1980 and the present time. More recently, two sets of data from the US, one from the California Public School system and another from the NIH-sponsored ECHO study, indicate that the prevalence of autism spectrum disorders (ASD) is increasing dramatically in a manner dependent on low socioeconomic status. Some evidence suggests that a potential adverse drug-drug interaction between acetaminophen and cannabis use disorder may underlie this trend, with an increase in cannabis use disorder resulting from the legalization of recreational cannabis use. Although increasing use of acetaminophen and potentially changing environmental factors that enhance acetaminophen toxicity can explain the sustained rise in ASD, data consistent with the acetaminophen/autism model continue to be misinterpreted by those considered experts in the field, hampering progress. Most errors involve over-correction for mediating factors in large sibling-controlled studies, although more recent data involving socioeconomic-dependent disparities in ASD prevalence have also been misinterpreted.
- Open Access
- 9 April 2026
- Published by MDPI AG in Preprints.org
An Update on the Connection Between Acetaminophen and Autism: Expanding Evidence and Misinterpreted Sibling Control Studies
More than 30 lines of discrete, independent evidence implicate the exposure of susceptible babies and children to acetaminophen with the etiology of autism spectrum disorder (ASD). The most abundant source of evidence is from the fields of pharmacology and toxicology, with clinical and epidemiological observations, numerous miscellaneous observations, and studies in laboratory animal models providing conclusive support. This narrative review summarizes that evidence, and discusses recent work with sibling control analysis that has been unfortunately misinterpreted as a result of incorrect assignment of interacting variables as confounding factors. Susceptibility to acetaminophen-induced injury is imposed by a range of genetic, epigenetic, and environmental factors associated with oxidative stress, and is apparently the greatest immediately after birth. Susceptibility then decreases until about six years of age, which is outside of the developmental window in which regression into ASD typically occurs. Although associations between heavy use of acetaminophen during pregnancy and ASD suggest some risk may be present during pregnancy, insufficient evidence is available to know if sporadic use of acetaminophen during pregnancy poses any risks. Given continued use of acetaminophen during labor and delivery, and routine use during early childhood including for indications including circumcision, vaccination, and some chronic medical conditions, a course correction in clinical practice is much needed.
- 9 April 2026
- Published by MDPI AG in Preprints.org
Open AccessAn Update on the Connection Between Acetaminophen and Autism: Expanding Evidence and Misinterpreted Sibling Control Studies
More than 30 lines of discrete, independent evidence implicate the exposure of susceptible babies and children to acetaminophen with the etiology of autism spectrum disorder (ASD). The most abundant source of evidence is from the fields of pharmacology and toxicology, with clinical and epidemiological observations, numerous miscellaneous observations, and studies in laboratory animal models providing conclusive support. This narrative review summarizes that evidence, and discusses recent work with sibling control analysis that has been unfortunately misinterpreted as a result of incorrect assignment of interacting variables as confounding factors. Susceptibility to acetaminophen-induced injury is imposed by a range of genetic, epigenetic, and environmental factors associated with oxidative stress, and is apparently the greatest immediately after birth. Susceptibility then decreases until about six years of age, which is outside of the developmental window in which regression into ASD typically occurs. Although associations between heavy use of acetaminophen during pregnancy and ASD suggest some risk may be present during pregnancy, insufficient evidence is available to know if sporadic use of acetaminophen during pregnancy poses any risks. Given continued use of acetaminophen during labor and delivery, and routine use during early childhood including for indications including circumcision, vaccination, and some chronic medical conditions, a course correction in clinical practice is much needed.
- Open Access
- 9 April 2026
- Published by MDPI AG in Preprints.org
Hypothesis: Emerging Evidence Might Suggest That Increases in Cannabis Use Disorder Following Legalization of Recreational Cannabis Significantly Contribute to Socioeconomic-Dependent Increases in the Prevalence of Autism Spectrum Disorder
A recent report on the prevalence of autism spectrum disorder (ASD) from California describes unprecedented levels of ASD in that population. The data indicate a transition or changepoint in 2015-2016 in which the prevalence of ASD began to accelerate more rapidly after almost a decade of consistent yearly increases. The changepoint is associated strongly with socioeconomic status, being most readily observable in black children and in low-income counties. Herein we propose the hypothesis that legalization of recreational cannabis in late 2016 led to several cultural changes that in turn caused socioeconomic-dependent increases in very frequent cannabis use and/or cannabis use disorder (CUD). CUD is strongly associated with ASD, and we hypothesize that an adverse drug-drug interaction between acetaminophen and a component or components of cannabis may be at play. It remains unknown whether prenatal or postnatal exposures may be more critical, and further work aimed at evaluating very frequent cannabis use and/or CUD and ASD rates in subsets of the population is strongly encouraged. Paradoxically, caution is urged so that work to decrease CUD does not impede ongoing and promising work using cannabis and cannabis-derived products for the treatment of patients with ASD.
- 9 April 2026
- Published by MDPI AG in Preprints.org
Open AccessHypothesis: Emerging Evidence Might Suggest That Increases in Cannabis Use Disorder Following Legalization of Recreational Cannabis Significantly Contribute to Socioeconomic-Dependent Increases in the Prevalence of Autism Spectrum Disorder
A recent report on the prevalence of autism spectrum disorder (ASD) from California describes unprecedented levels of ASD in that population. The data indicate a transition or changepoint in 2015-2016 in which the prevalence of ASD began to accelerate more rapidly after almost a decade of consistent yearly increases. The changepoint is associated strongly with socioeconomic status, being most readily observable in black children and in low-income counties. Herein we propose the hypothesis that legalization of recreational cannabis in late 2016 led to several cultural changes that in turn caused socioeconomic-dependent increases in very frequent cannabis use and/or cannabis use disorder (CUD). CUD is strongly associated with ASD, and we hypothesize that an adverse drug-drug interaction between acetaminophen and a component or components of cannabis may be at play. It remains unknown whether prenatal or postnatal exposures may be more critical, and further work aimed at evaluating very frequent cannabis use and/or CUD and ASD rates in subsets of the population is strongly encouraged. Paradoxically, caution is urged so that work to decrease CUD does not impede ongoing and promising work using cannabis and cannabis-derived products for the treatment of patients with ASD.